摘要
目的:探讨慢性肝病患者血浆凝血酶激活的纤溶抑制物活性(TAFI:A)、纤溶酶原激活物抑制剂(PAI-1)及组织型纤溶酶原激活物(t-PA)水平变化的临床意义。方法:收集84例临床肝病患者的血液标本,同时选取52例体检健康者为对照组,TAFI:A测定采用发色底物法,PAI-1、t-PA含量测定采用ELISA法,并统计分析上述3项指标与不同类型慢性肝病间的相关性。结果:与对照组比较,病例组血浆TAFI:A水平均显著降低(P<0.05);血浆PAI-1水平显著增加(P<0.05);血浆t-PA水平亦显著增加(P<0.05,原发性胆汁性肝硬化除外)。结论:慢性肝损伤患者血浆TAFI:A水平降低,导致纤溶活性增加,是提示慢性肝病患者呈出血倾向的一项指标。
Objective：To study the correlation between chronic liver damage and thrombin-activatable fibrinolysis inhibitor（TAFI）through detecting the levels of（TAFI）in patients with chronic liver disease.Method：TAFI：A,plasminogen activator inhibitor（PAI-1）and tissue plasminogen activator（t-PA）were tested within 84 patients with chronic liver disease and 52 cases of healthy controls,using chromogenic assay and ELISA kits.Appropriate statistical methods were used to analyze the experimental results.The value of TAFI and its correlations with chronic liver damage were analyzed.Result：The level of TAFI was significantly lower in chronic liver disease patients than that in control group（P〈0.05）.Compared with the control group,the level of PAI-1 was greatly increased in chronic liver damage patients（P〈0.05）.The level of t-PA was significantly higher in chronic liver disease patients than that in control group（P〈0.05）excepting primary biliary cirrhosis.Conclusion：A reduction in TAFI may be one of the more important and potentially critical determinants of the low-grade fibrinolysis seen in chronic liver disease.
出处
《临床血液学杂志（输血与检验）》
CAS
2013年第4期546-548,共3页
Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
关键词
凝血酶激活的纤溶抑制物
纤维蛋白溶解
慢性肝病
thrombin-activatable fibrinolysis inhibitor（TAFI）
plasminogen activator inhibitor（PAI-1）
tissue plasminogen activator（t-PA）
chronic liver disease
